GSK Plans to Increase Stake in Indian and Nigerian Subsidiaries - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GSK Plans to Increase Stake in Indian and Nigerian Subsidiaries


ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline (GSK) announced its intent to increase ownership in GlaxoSmithKline Consumer Healthcare Ltd, its publicly-listed subsidiary in India, from 43.2% to up to 75% and, in a separate release, announced an agreement in principle on a proposal to increase ownership in GlaxoSmithKline Consumer Nigeria PLC from 46.4% to 80%. The offers represent the maximum possible stake allowed while maintaining a public listing in the respective countries and are part of GSK’s strategy to invest in emerging markets.

“GSK Consumer Healthcare is a well-established business in India, and its leading product, Horlicks, is an iconic household brand.  This transaction represents a further step in GSK's strategy to invest in the world's fastest growing markets and, we believe, offers a liquidity opportunity at an attractive premium for existing shareholders," said David Redfern, GSK chief strategy officer, in the press release.

The transaction in India, valued at up to approximately $940 million, will be funded through GSK’s existing cash resources, will be earnings neutral for the first year and accretive thereafter, and will not impact expectations for the Group’s long-term, share-buyback program. Subject to regulatory clearance, the offer period is expected to begin in January 2013.

The board of directors of GSK Nigeria unanimously approved the proposal and intends to recommend it to shareholders. Under the terms of the deal, GSK would acquire approximately 321 million shares in the company on a pro rata basis from public shareholders for a total value of almost $98 million. The transaction in Nigeria will be funded through GSK’s existing cash resources, will be modestly earnings accretive immediately, and will not impact expectations for the Group’s long-term, share-buyback program. The proposal will be subject to requisite shareholder, regulatory, and court approvals including those of the Nigerian Stock Exchange and the Securities and Exchange Commission.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here